Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:56 2024-04-26 am EDT			5-day change	1st Jan Change
1,954 ^DKK	+2.04%		-2.57%	-9.30%

Apr. 16	Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug	MT
Apr. 16	Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024	CI

Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 1, 2021.

February 14, 2024 at 12:31 pm EST

From October 1, 2023 to December 31, 2023, the company has repurchased 0 shares, representing 0% for DKK 0 million. With this, the company has completed the repurchase of 790,000 shares, representing 1.21% for DKK 1,917.75 million under the buyback announced on March 1, 2021.

Latest news about Genmab A/S

Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug	Apr. 16	MT
Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024	Apr. 16	CI
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Health Care Flat on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	Apr. 03	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET	Apr. 03	DJ
Global markets live: Swiss Re, Intel, Walt Disney, Paramount, Microsoft...	Apr. 03
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET	Apr. 03	DJ
Correction to Genmab Article	Apr. 03	DJ
Genmab: acquisition of ProfoundBio greeted without emotion	Apr. 03	CF
News Highlights : Top Company News of the Day - Wednesday at 7 AM ET	Apr. 03	DJ
Genmab A/S Re-Affirms Revenue Guidance for the Year 2024	Apr. 03	CI
Transcript : Genmab A/S, ProfoundBio - M&A Call	Apr. 03
European Midday Briefing : Stocks Continue to Struggle Despite Cooling Inflation	Apr. 03	DJ
News Highlights : Top Company News of the Day - Wednesday at 5 AM ET	Apr. 03	DJ
Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio	Apr. 03	DJ
Genmab Looks to Expand Clinical Pipeline with $1.8 Billion Purchase of Cancer-focused ProfoundBio	Apr. 03	MT
Denmark's Genmab to acquire ProfoundBio for $1.8 billion	Apr. 03	RE
Genmab to Acquire ProfoundBio for $1.8 Billion	Apr. 03	MT
Genmab to Purchase US-based ProfoundBio for $1.8 Billion	Apr. 03	MT
Genmab A/S entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.	Apr. 02	CI
Genmab A/S commences an Equity Buyback Plan under the authorization approved on March 13, 2024.	Mar. 25	CI
Genmab Completes Share Buyback Program	Mar. 18	MT
Tranche Update on Genmab A/S's Equity Buyback Plan announced on February 14, 2024.	Mar. 18	CI
Genmab to Repurchase Up to $511 Million Shares	Mar. 15	MT
Genmab A/S's Equity Buyback announced on February 14, 2024, has closed with 190,000 shares, representing 0.29% for DKK 378.72 million.	Mar. 14	CI

Chart Genmab A/S

Duration

Period

More charts

Company Profile

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GENMAB : Genmab is available at a bargain price

March 04, 2024 at 06:10 am EST

More Strategies

Ratings for Genmab A/S

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,954 DKK

Average target price

2,418 DKK

Spread / Average Target

+23.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENMAB A/S	-9.30%	18.15B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B
LEGEND BIOTECH CORPORATION	-24.71%	8.24B

Bio Therapeutic Drugs